GMP licensing scope expansion is quite a lucrative area. For...

GMP licensing scope expansion is quite a lucrative area.

For other local Cannabis producers, this provides a contracting facility for numerous processes in their sales pipeline.

Building the solid foundations for a B2C sales team also increases exposure of the products and brand to the consumers through their access pathway (GPs). We have seen the number of prescribers registered as well as prescriptions expand exponentially in Australia. One would expect margins to increase substantially over the coming FY as things start to fall into place.

The unofficial launch of VESIsorb gives the ECS product a clear first mover advantage in at least the Australian market for higher bioavailability products. All health professionals, myself included, understand the burden of financial expenses to medication prescriptions. A product available at perhaps a slight premium, that delivers a longer lasting prescription (overall cost savings) is more often than not the gold standard in therapy.

I strongly believe we have seen the bottom in our SP due to factors outside of the market determined means (AK…).